Takeda's orteronel misses PhIII endpoint in post-chemo prostate cancer
This article was originally published in Scrip
Takeda has had to unblind an international Phase III trial with its novel prostate cancer drug orteronel (TAK-700) in post-chemotherapy patients after an interim analysis showed the ELM-PC 5 (C21005) study would miss its primary endpoint of improved overall survival.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.